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Abstract
Background: HIV-infected patients starting antiretroviral treatment (ART) experience deep and early disorders in fat
and bone metabolism, leading to concomitant changes in fat mass and bone mineral density.
Methods: We conducted a prospective study in treatment-naive HIV-infected patients randomized to receive two
nucleoside reverse transcriptase inhibitors in combination with either a protease inhibitor (PI) or a non-nucleosidic
reverse transcriptase inhibitor (NNRTI), to evaluate early changes in body composition, bone mineral density and
metabolic markers as differentially induced by antiretroviral therapies. We measured changes in markers of
carbohydrate, of fat and bone metabolism, and, using dual-emission X-ray absorptiometry (DXA), body composition
and bone mineral density (BMD). Complete data on changes between baseline and after 21 months treatment
were available for 35 patients (16 in the PI group and 19 in the NNRTI group).
Results: A significant gain in BMI and in total and lower limb fat mass was recorded only in patients receiving PI.
A loss of lumbar BMD was observed in both groups, being higher with PI. Plasma markers of bone metabolism
(alkaline phosphatase, osteocalcin, collagen crosslaps) and levels of parathormone and of 1,25diOH-vitamin D3
significantly increased in both groups, concomitant with a decline in 25OH-vitamin D3. Lipids and glucose levels
increased in both groups but rise in triglyceride was more pronounced with PI. A correlation between loss of BMD
and gain of fat mass is observed in patients starting PI.
Conclusions: We evidenced an early effect of ART on lipid and bone metabolisms. PI lead to a significant gain in
fat mass correlated with a sharp drop in BMD but active bone remodelling is evident with all antiretroviral
treatments, associated with low vitamin D levels and hyperparathyroidism. In parallel, signs of metabolic restoration
are evident. However, early increases in lean and fat mass, triglycerides, waist circumference and leptin are much
more pronounced with PI.
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Background
Selective effects of nucleoside reverse transcriptase
inhibitors (NRTI) and of protease inhibitors (PI) on
adipose tissue differentiation and on lipid metabolism
have been described [1,2]. More recently, attention was
focused on loss of bone mineral density (BMD) recorded in
HIV-infected patients [3]. Prevalence of osteoporosis and
osteopenia was found about twice higher in HIV-patients
than in seronegative controls [4,5]. In a large population-
based study, occurrence of pathological fractures was more
frequent in HIV-patients [6]. Several studies have also
documented low levels of vitamin D in HIV-patients, while
fragments of bone collagen degradation were found el-
evated [7-10]. However, contrasted observations have
been made regarding other markers, like parathormone or
osteocalcin [7,8]. A few longitudinal studies have addressed
the issue of bone loss, but patients were already treated at
baseline and time of follow-up was very variable, leading to
contradictory conclusions [11,12]. In order to monitor early
changes in body composition and BMD, we implemented a
prospective study – LIPOTRIP -, following up treatment-
naive HIV-infected patients, randomized to receive either a
non-nucleosidic reverse transcriptase inhibitor (NNRTI) or
a PI-based regimen. In parallel, we evaluated the changes
in markers of lipid and bone metabolism and looked
for correlations between changes in body composition
and BMD. This study enables the description of differential
effects of treatments on BMD, body composition and
metabolic changes.
Methods
A prospective study was set up, following up naive HIV-
infected patients commencing ART, enrolled between
January 2004 and April 2006. Using a random number
table, they were assigned to either one of two thera-
peutic schemes: first group patients were treated with
two NRTIs and a ritonavir-boosted PI (“PI group”)
while second group patients received two NRTIs and a
NNRTI (“NNRTI group”). Physicians had some recommen-
dations for preferred regimens: ZDV-3TC+ EFV in NNRTI
group and ZDV-3TC + any PI in the PI group. However,
at the time the study started fosamprenavir / ritonavir was
extensively used.
Inclusion criteria were adult HIV-infected patients
(age > 18 years) naive of ART. Patients with current or
recent (< 1 month) opportunistic diseases were excluded
from the study as were those with diabetes mellitus, known
dyslipidaemia, alcoholism, obesity, Cushing syndrome,
thyroid disease, menopause, corticosteroid treatment
and anyone who could not sustain an 8-hour fasting.
All patients had signed informed consent and the
protocol was approved by the local Ethics Committee
(“Protection Committee of people for Biomedical Research”,
Toulouse 1. France). At baseline and every three months
thereafter, clinical and biological data were collected, includ-
ing weight and BMI, CD4-cells and other blood cell counts,
HIVviral load, haemoglobin level, ionogram and creatin-
ine concentration, biomarkers of carbohydrate, lipid and
bone metabolism. Body composition was evaluated by
DXA at baseline and after 9 (M9) and 21 months (M21)
on treatment. Seventy three patients were screened and
70 were enrolled in the study. Complete data at baseline,
9 and 21 months were available for 35 patients, as shown
in Figure 1).
The relatively small proportion of patients for whom
complete data were available at 21 months can be largely
explained by the constraints of laboratory tests including a
glucose tolerance test and because the site where the DXA
was performed was quite distant from the consultation site.
Biological measurements
Blood was collected after an overnight fast, CD4 lympho-
cytes were determined by flow cytometry and plasma HIV
viral load was measured by quantitative PCR. Serum glu-
cose, triglycerides, cholesterol and high-density lipoprotein
(HDL)-cholesterol were assayed with enzymatic reagents on
an automated analyzer (Roche Diagnostics, Meylan, France).
Low-density lipoprotein (LDL)-cholesterol was calcu-
lated using the Friedwald equation. Serum lactate was
assayed in an automated analyzer (Olympus, Les Ulis,
France), as were activities of total alkaline phosphatase
(ALP) and γ-glutamyltranspeptidase (γGT) assayed at
37°C. Pyruvate was assayed with an enzymatic method.
Albumin concentration was determined by a direct col-
orimetric assay (Olympus). Osteocalcin and β-crosslaps,
representing the C-ter telopeptides of type I collagen,
and PTH (1–84) were measured by two-site immuno-
assays using electro-chemiluminescence signals in a
Roche analyzer. The 25- hydroxyl-vitamin D3 (25-OH D3)
was determined using an automated immunoassay
(Liaison, DiaSorin, Les Ulis, France), cross-reacting
with the parent 25-OH-vitamin D2. Bone ALP and 1,25-
dihydroxyl-vitamin D3 (1,25-diOH D3) were measured by
specific radioimmunoassay (Becton-Dickinson, Marseille,
France). Insulin was measured by an immunoassay using
a chemi-luminescence signal on an automated analyzer
(Advia-Centaur, Siemens HealthCare Systems). Leptin was
measured by a specific radioimmunoassay (Millipore Corp,
St. Charles, Missouri, USA).
Densitometric measurements
All determinations were done with the same device: the
DPX-L (Lunar Corporation®), and acquisition and ana-
lysis software 4.6. We determined total lean and fat
masses, lower limb lean and fat masses, trunk lean and
fat masses and fat mass ratio (FMR), defined as the ratio
of % trunk fat mass over % leg fat mass. Values of BMD
obtained from measurements at the hip and whole body
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were found to be congruent for the general population.
Thus, in order to simplify analyses by DXA, we decided
to measure whole body BMD, as an indicator of BMD in
cortical bone. We also measured BMD at the lumbar




In bivariate analyses, chi-square test was used to compare
the distribution of qualitative variables between treatment
groups. When asymptotic chi-square was not appropriate,
the Fischer’s exact test was performed. Mean values of
continuous variables were compared by Student’s t-test.
The Shapiro-Wilks and Levene’s tests were used to check
the normality of the distribution of residuals and the homo-
geneity of variances, respectively. When basic assumptions
were not satisfied for Student’s t-test, a logarithmic
transformation of the variable was done. Log-transformed
variables were used for all subsequent analysis.
Multivariate analyses
Subjects were measured over time as repeated measure-
ments data. We used linear mixed effects models to fit
response trends over time and to determine treatment
group effects (i.e. interaction of treatment X period).
Random intercept and random slope were taken into
account to model heterogeneity in intercepts and in slopes
of the individual’s own regression line for repeated mea-
surements data. The treatment x period interaction was
systematically sought for each parameter analysed and was
considered as statistically significant for p <0.10. A stratified
analysis by treatment group was conducted to test specific
changes over time. A systematic adjustment for age, sex
and geographical origin of individuals was done. The level
of significance was set at p < 0.05. Statistical analyses were
performed using the SAS statistical software, release 9.1
(SAS Institute Inc, Cary, North Carolina, U.S.A.).
Results
Baseline characteristics of patients according to
treatment groups
Naive HIV-infected patients were randomly assigned to
either one of two therapeutic schemes. All patients started
a treatment containing two NRTIs: zidovudine + lamivudine
[51.5%], tenofovir + emtricitabine (or lamivudine) [20.6%],
didanosine + lamivudine (or emtricitabine) [14.7%], abacavir +
lamivudine [13.2%], these frequencies being similar in the
two treatment groups. In the PI group, patients received
the following drugs: fosamprenavir [54.3%], atazanavir
[20%], saquinavir [11.4%], indinavir [8.6%], lopinavir [5.7%],
all being boosted with ritonavir. In the NNRTI group
they received either efavirenz [68.6%] or nevirapine [25.7%].
Complete data (including DXA results and all biological
parameters at 9 and 21 months) were available from 35
subjects, who did not switch ART during the study period
and were equally distributed in the two treatment groups.
The number of patients lost to follow-up was similar in
the 2 groups, and baseline data were identical for patients
lost to follow-up and those included in the final analysis
(data not shown) (Table 1).
Individual characteristics are compared in Table 1.
Males constituted about two thirds of the population
study and mean age was 42 years. Seventy-five percent
Patients screened.
N = 73
Patients enrolled and randomized (complete data at baseline)
N = 70
PI group
N = 35 (at baseline) 
NNRTI group
N = 35 (at baseline)
Complete data at Month 21
N = 16
Complete data at Month 21
N = 19
Figure 1 Patients screened, enrolled, randomized, and analyzed in the study.
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of included subjects were of European ascent and 25%
of African origin. Most African patients were women
(8 out of 10). Proportions of Africans and of females
were similar in both groups. Duration of the diagnosed
infection before ART initiation was about 2 years. Dis-
tribution among the clinical stages of the disease was
similar between the two groups, with less than 20% of
included patients at stage C.
Viral load at baseline was close to 5 log 10 copies/ml
and average CD4 numbers was 240 in the two groups.
Anthropometric measurements gave normal average
values for BMI and waist circumference. Likewise, deter-
minations of body composition indicated identical body
fat mass and lean mass in the two groups. The FMR, a
reliable marker of alterations of fat distribution [13],
was in the normal range for both men (below 1.5) and
women (less than 1.0) in the two treatment groups.
Likewise, BMD in the whole body and at the lumbar
spine were very close to that of the general population
and similar in the two groups, as were the markers of
bone differentiation (bone ALP and osteocalcin) and
resorption (ß-cross-laps).
Interestingly, levels of 25-OH-D3 were similar between
groups and below recommended values (> 25 μg/l). How-
ever, the active form, 1,25-dihydroxyl-vitamin D3, was in
the normal range (35–70 ng/l).
Smoking habits were different, as 31% of the NNRTI
group subjects were still smokers versus none in the PI
group. Glucose, liver enzymes and alkaline phosphatase
(ALP) were found normal and identical between groups,
as were lactate, pyruvate, insulin and leptin (not shown).
However, plasma lipids, particularly cholesterol, were
somewhat lower in the NNRTI group.
Changes in immuno-virological parameters during
treatment
The two allocated therapeutic schemes were equally ef-
fective in restoring total and CD4 lymphocytes, as well
as in controlling viral load (Table 2).
Changes in body composition and metabolic markers
during treatment
BMI regularly increased with time, significantly only in
the PI group; where a 8% rise was recorded in this group
(Figure 2). A parallel increase in waist circumference
was also recorded in the PI group. Changes in BMI were
paralleled by variations of body composition. After
21 months upon PI, lean mass was enhanced by 5% and
fat mass in higher proportions (+16%). Both trunk and
limbs gradually increased their fat mass with time so
that the FMR was unmodified during this follow-up
period (not shown). PI-sparing treatments did not lead
to alterations of body composition (Figure 3). Significant
rises with time were also recorded for lipids. After
21 months, total and LDL-cholesterol were enhanced
by about 25%, but remained in normal ranges. HDL-
cholesterol, being low at baseline, was restored to normal
values with both treatments (> 0.4 g/l), yet the increase
was much more pronounced in the NNRTI group.
Regarding triglycerides, a significant rise was observed in
the PI-group only (Figure 3), reaching levels above
upper normal limits (> 1.5 g/l). Rises in plasma albumin
Table 1 Baseline characteristics of patients according to
treatment groups: clinical, immunovirological and body







Age, y 42.3 (14.5)* 39.7 (11.9)* 0.57
Sex ratio (M,%) 62.5 63.2 0.96
Origin 0.96
European (%) 75.0 73.7
African (%) 25.0 26.3
Current smokers (%) 0 31.6 0.03
Duration of diagnosed
infection, years
2.2 (2.9)* 1.6 (1.8)* 0.46
CDC categories 0.31
A + B (%) 81.3 94.7
C (%) 18.7 5.3
Viral load (log10/ml) 5.05 (0.85)* 5.04 (0.55)* 0.97
CD4 lymphocytes/ml 240 (153)* 240 (131)* 0.90
BMI, kg/m2 23.8 (3.6)* 24.0 (3.6)* 0.84
Body Lean Mass, kg 46.3 (8.8)* 49.4 (10.3)* 0.35
Body Fat Mass, kg 18.4 (8.9)* 19.4 (10.9)* 0.79
Fat Mass ratio 0.97 0.97 0.99
In men 1.05 (0.16)* 1.03 (0.14)* 0.81 ≤ 1.5
In women 0.85 (0.10)* 0.87 (0.14)* 0.74 ≤ 1.2
BMD L2-L4 (g/cm2) 1.233 1.249 0.82
Cholesterol, g/l 1.88 (0.45)* 1.61 (0.34)* 0.05 1.5 – 2.2
HDL-cholesterol, g/l 0.44 (0.08)* 0.38 (0.10)* 0.10 > 0.4
Triglycerides, g/l 1.14 (0.58)* 0.99 (0.48)* 0.46 0.5 – 1.5
Glucose, g/l 0.84 (0.08)* 0.83 (0.09)* 0.79 0.72 - .1.05
Total alkaline
phosphatase, U/l
168 (37)* 173 (49)* 0.73 100 – 280
Bone alkaline
phosphatase, μg/l
8.1 (3.2)* 8.3 (2.6)* 0.88 5 – 20
β-Cross-laps, μg/l 353 (186)* 302 (161)* 0.39 160 – 440
25-OH-vitamine D3, μg/l 20.7 (8.2)* 19.4 (12.0)* 0.71 22 – 45
1,25-di-OH-vitaminne
D3, ng/l
49.1 (18.7)* 49.3 (18.4)* 0.97 25 – 60
Parathormone, ng/l 34.1 (12.9)* 35.1 (13.3)* 0.83 10 - 65
Cockroft (ml/min) 83.9 (21.9)* 102.3 (17.3)* 0.01
* mean value (standard deviation).
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and glucose during treatment were evidenced, being
significant upon PI for albumin, and upon NNRTI for
glycaemia. Finally, leptin measurements were available
up to 9 months showing a differential response to treat-
ments: leptin concentration was stable upon NNRTI
(6.9 ± 7.3 μg/L at month 0 and 6.7 ± 6.8 μg/L at month 9),
but sharply increased upon PI from (from 9.0 ± 10.8 to
13.8 ± 12.7 μg/L, p = 0.04).
Changes in bone mineral density and markers of bone
metabolism during treatment (Table 2)
Following a 21-month ART, an average 3% reduction of
lumbar spine BMD was evident. Bone mineral loss was
different between treatments: drop in L2-L4 density was
1.5% (p < 0.04) in the NNRTI group and 4% (p < 0.001) in
the PI group (Figure 2). In either men or women, we found
no statistical interaction between treatment time and
ethnicity. Significant changes in L2-L4 BMD were also
recorded when analyses were conducted separately in
males (p = 0.001) and in females (p = 0.04). However,
African and European women were quite different regarding
basal L2-L4 BMD: 1.400 (± 0.224) versus 1.089 (± 0.169),
respectively (p < 0.01). Moreover, African women expe-
rienced smaller decreases upon treatment: - 0.018 ver-
sus −0.045 g/cm2 in European counterparts (p < 0.05,
not shown). It is noteworthy no woman underwent
menopause during follow-up. A subanalysis combining
gender and ethnicity was not possible due to the small size
of subgroups. In both groups, cross-laps, representing
markers of collagen degradation, were increased by
50% during follow-up. In parallel, osteocalcin, was 70%
increased. Total ALP was increased in both groups and
Table 2 Changes in immuno-virological, haematological and metabolic markers, anthropometric and body composition
parameters, and in bone markers as a function of treatment time
+ PI + NNRTI
(n = 16) (n = 19)
Parameter* Month 0 Month 9 Month 21 p, trend Month 0 Month 9 Month 21 p, trend p, time X treatment
interaction
CD4 lymphocytes /ml 240 (153) 376 (158) 497 (189) 0.001 241 (131) 445 (167) 493 (127) 0.001 0.54
Viral load, log10/ml 5.05 (0.85) 2.08 (0.85) 1.62 (0.07) 0.001 5.04 (0.55) 1.91 (0.88) 1.59 (0.01) 0.001 0.99
Cholesterol, g/l 1.88 (0.45) 2.22 (0.66) 2.29 (0.41) 0.001 1.61 (0.34) 1.95 (0.46) 2.03 (0.41) 0.001 0.99
HDL-cholesterol, g/l 0.44 (0.08) 0.45 (0.10) 0.52 (0.15) 0.06 0.38 (0.10) 0.52 (0.16) 0.56 (0.16) 0.001 0.003
Triglycerides, g/l 1.14 (0.58) 1.99 (1.68) 1.75 (0.82) 0.002 0.99 (0.48) 1.34 (1.64) 1.31 (0.97) 0.26 0.06
Glucose, g/l 0.84 (0.08) 0.88 (0.08) 0.87 (0.07) 0.14 0.83 (0.09) 0.94 (0.08) 0.90 (0.07) 0.001 0.08
Lactate, mmoles/l 0.93 (0.28) 1.06 (0.39) 1.11 (0.44) 0.24 0.98 (0.28) 0.94 (0.24) 0.93 (0.35) 0.68 0.19
Albumin, g/l 39.0 (4.9) 42.6 (2.0) 42.5 (2.0) 0.006 41.7 (3.7) 43.1 (3.5) 42.9 (2.5) 0.07 0.05
Cockroft (ml/min) 83.9 82.9 86.1 0.73 102.3 103.1 104 0.66 0.97
Waist circumference, cm 83.2 (11.3) 87.5 (16.7) 89.7 (13.7) 0.04 82.3 (7.4) 82.5 (8.3) 81.9 (9.1) 0.51 0.03
BMI, kg/m2 23.6 (3.6) 25.0 (4.9) 25.7 (5.5) 0.02 23.9 (3.6) 24.0 (3.7) 24.3 (3.7) 0.73 0.03
Body Mineral content, kg 3.02 (0.69) 2.97 (0.63) 2.93 (0.58) 0.06 3.11 (0.56) 3.08 (0.57) 3.04 (0.53) 0.008 0.58
L2-L4 BMD, g/cm2 1.234 1.182 (0.226) 1.186 (0.238) 0.001 1.249 (0.178) 1.232 (0.196) 1.230 0.04 0.05
(0.234) (0.176)
Body lean mass, kg 46.3 (8.8) 48.2 (10.9) 48.9 (11.2) 0.05 49.4 (10.3) 49.6 (9.6) 49.8 (10.2) 0.64 0.09
Body fat mass, kg 18.4 (8.9) 20.2 (11.1) 21.5 (10.4) 0.02 19.4 (10.9) 19.5 (10.2) 19.6 (9.4) 0.79 0.05
Trunk fat mass, kg 8.87 (4.38) 9.43 (5.28) 10.28 (4.80) 0.03 9.03 (4.69) 9.12 (4.57) 9.49 (4.54) 0.42 0.19
Legs fat mass, kg 6.61 (3.39) 7.51 (4.16) 8.00 (4.24) 0.02 6.88 (4.18) 7.29 (4.38) 7.12 (3.70) 0.35 0.07
Total ALP U/l 168 (37) 193 (75) 208 (82) 0.04 173 (49) 227 (67) 221 (53) 0.001 0.47
Osteocalcin, μg/l 19.3 (7.6) 37.8 (15.0) 29.7 (12.8) 0.003 15.7 (5.1) 24.5 (8.5) 22.6 (12.6) 0.005 0.19
ß-crosslaps, μg/l 353 (186) 552 (267) 525 (240) 0.03 302 (161) 582 (277) 473 (226) 0.001 0.56
Calcium, mmoles/l 2.28 (0.08) 2.34 (0.10) 2.36 (0.08) 0.02 2.29 (0.11) 2.32 (0.15) 2.32 (0.13) 0.31 0.22
25-OH vitamine D3, μg/l 20.7 (8.2) 22.1 (9.1) 16.4 (7.2) 0.27 19.4 (12.0) 19.5 (12.7) 15.7 (9.6) 0.12 0.81
1,25—diOH-vit D3, ng/l 49.1 (18.7) 42.9 (8.3) 58.9 (16.6) 0.29 49.3 (18.4) 51.6 (17.6) 61.1 (14.7) 0.04 0.54
Parathormone, ng/l 34.1 (12.9) 36.7 (12.7) 53.4 (20.0) 0.01 35.1 (13.3) 47.8 (19.6) 46.5 (12.5) 0.001 0.78
* mean value (standard deviation).
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a doubling of bone ALP was recorded between baseline
and month 9 (p < 0.001, not shown). Mean value for bone
ALP, osteocalcin and ß-cross laps exceeded upper normal
limits (see Table 1).
Serum calcium displayed a slight increase with time,
significant in the PI group. Levels of 25-OH-D3 remained
stable at month 9, but tented to fall by 20% during the next
12 months. Considering the whole population, this trend
was close to significance (p = 0.07). Conversely, in the two
groups, PTH increased significantly with time. In parallel,
the active 1,25-diOH-D3 increased by 25% at 21 months,
significantly in the NNRTI group. However, the difference
between groups of 1,25-diOH D3 increase at 21 months
was not significant (p = 0.54).
Alterations in markers of bone turnover or of calcium
homeostasy were observed with both antiretroviral strat-
egies. It is noteworthy that no patient had received vitamin
D supplementation during the study period. Eight patients
received tenofovir and twenty-five, did not. Changes in
value of BMD, 25-OH-D3 and 1,25-diOH-D3 did not dif-
fer significantly according to whether or not patients were
treated with tenofovir (data not shown).
Figure 2 Changes in BMI and bone mineral density as induced by two different ARV modalities. BMI regularly increased with time, a
significant 5% rise was recorded only in the PI group. Following a 21-month ART (M21) an average 3% reduction of lumbar spine BMD was
observed. Bone mineral loss was different between treatments: drop in L2-L4 density was 1.5% the NNRTI group and 4% in the PI group.
Figure 3 Changes in body fat mass and in plasma triglycerides as induced by two different ARV modalities. In the PI group, but not in
the NNRTI group, there was a significant and marked rises in fat content. For triglycerides (TG), a significant rise was observed in the PI-group
only, reaching levels above upper normal limits (> 1.5 g/l).
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Correlations between changes in bone mineral density
and BMI or biological markers
In the PI group, changes in L2-L4 density were nega-
tively correlated with variations of BMI (− 0.68, p < 0.05)
(Figure 4), lean mass (r = − 0.71, p < 0.01) (data not
shown) and albumin concentration (r = − 0.58, p < 0.05)
(data not shown). A non-significant inverse association
with trunk fat mass was also observed in the PI-group
(data not shown).
This suggests that patients who experience the best
metabolic restoration upon treatment are more prone to
develop osteopenia. No such relationship was found in
the NNRTI group. Further on, we compared simultan-
eous variations upon treatment of L2-L4 BMD and of
various biomarkers. In both groups, changes in BMD
were negatively correlated with variations of osteocalcin
and β-cross-laps: bone loss was more pronounced when
osteocalcin displayed the strongest increase (r = − 0.52
in the PI-group and – 0.65 in the NNRTI-group, p <
0.05) (data not shown).
Discussion
The present study had a controlled prospective design,
with treatment-naive patients randomly allocated to a first
ART. It clearly shows that PI administration induces a sig-
nificant decrease in lumbar spine BMD. Many cross-
sectional studies and few longitudinal studies have investi-
gated alterations of body composition in HIV-infected
patients under various treatments. All those studies con-
cluded to a low BMD in infected men and women, par-
ticularly when measured at the lumbar spine [3,12,14,15].
In a large French cohort of 35–50 years-old patients,
prevalence of osteoporosis was 34% in men and 8% in
women, and osteopenia was diagnosed in 50–55% [5]. Dif-
ferences were also observed depending on ethnicity:
osteopenia was found twice more frequent in Caucasians
than in Africans [9]. Finally, a low BMD may have a clin-
ical impact as prevalence of vertebral, hip or wrist
fractures was 65% higher in HIV-patients than in healthy
age-paired counterparts [6]. Components of the HIV itself,
like Gp 120, might be involved in impairing osteoblast dif-
ferentiation while promoting their apoptosis [16]. In the
present study, baseline BMD was not lower than in the
general population at the same age and in the same area.
These results are not consistent with those published by
others and ourselves [3,8,17-19]. These discrepancies can
be explained by a shorter duration of HIV infection in the
present study as compared with previous studies. It is
recognised that HIV infection itself is a risk factor for
osteopenia [16]. This effect seems to be correlated with
the duration of infection as reported in other chronic in-
fections (e.g. HBV and HCV infections) [20].
Regarding impact of different classes of ART, conflicting
data have been reported. While some studies claimed
that low BMD is observed irrespective of treatments
[21], others have found a strong association with use of
PI [17,22], of NRTI [12] or of Tenofovir [14]. Large
meta-analyses have concluded to a 2.4-fold higher risk of
osteoporosis attributable to ART [16,17]. The study
by Duvivier et al. [15] including 3 groups of patients
(NNRTI + PI, 2 NRTI +NNRTI, 2 NRTI + PI) also con-
cluded to a more pronounced decrease in lumbar spine
BMD in patients receiving either PI-containing regimen as
compared with the NNRTI and NRTI group. Except for
the presence of a third group of patients treated with PI +
NNRTI, the design of this study and the characteristics of
the patients and groups were fairly close to those of our
study. However, the longer duration of observation in our
study (90 weeks vs 48 weeks) enables to demonstrate that
the more pronounced decrease of BMD in PI-treated pa-
tients occurred during the first months of therapy, as also
shown in a prospective study comparing the effects on
bone density of regimens containing atazanavir or
efavirenz [23]. After the first 9 months of treatment, BMD
remained stable, whether patients received PI or NNRTI.
Moreover, we had measurements of markers of bone
BMI
L2-L4 BMD
Figure 4 Simultaneous variation of BMI and BMD in the PI group, between the baseline and the end of the ninth month of treatment
(M9). Changes in L2-L4 density were negatively correlated with variations of BMI (β = -0.682, 95%CI [-0.831;-0.879], p < 0.05).
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turn-over and body composition and found correlations
between these variables and the BMD decrease. Bone loss
following ART initiation seems to coincide with immune
reconstitution, which causes a high bone resorption [24].
Although the measured variations are partly dependent
on sex and ethnicity, this cannot explain the differences
between our groups, as the proportions of Africans and of
women were identical. However, this study confirms that
BMD changes were more pronounced in Europeans than
in Africans.
At a variance with changes in body composition, markers
of bone build-up (bone ALP, osteocalcin) and resorption (β-
cross-laps) were stimulated with either therapeutic scheme.
This suggests that bone turnover is activated as soon as a
minimal mineral loss has occurred. Cross-sectional studies
have reported elevated levels of collagen degradation frag-
ments and of osteoblast specific proteins in HIV-infected
adults and children [25-27], particularly when treated with
PI [8]. Although parameters of bone turn-over were not
discriminators between treatment groups, changes in
osteocalcin and cross-laps were significantly associated
with the magnitude of osteopenia making them useful
markers to follow-up treated HIV-patients.
Experiments in cultured cells may help to elucidate
the molecular mechanisms underlying bone alterations
upon ART. Regarding osteoclast differentiation, several
antiretroviral molecules have demonstrated an impact
on the RANK ligand (receptor activator of NF-КB lig-
and) pathway (RANKL) leading to its sustained activa-
tion [28,29]. Interestingly, leptin concentration sharply
increased upon PI. Leptin, acting through its hypothal-
amic receptor, plays an indirect role in bone resorption,
through stimulation of the sympathetic tone. Activation
of the β2-adrenergic receptor in osteoblasts stimulates
RANKL expression [30]. Moreover, increase in leptin
upon PI may reflect development of peri-visceral,
insulin-resistant, adipose tissue, as suggested here by the
increased waist circumference. Hyperleptinemia, corre-
lated with insulin resistance has been recently reported
in HIV-patients under ART [31].
ln our study, baselevels of 25-OHD3 were below
recommended values. Further on, at 21 months upon
ART, a 20% decline in 25-OH D3 was recorded (p = 0.07
for the whole population). However, clinicians have not
performed supplementation before the study because 25-
OH D3 levels were not measured before the study. Supple-
mentation was anyway an exclusion criterion. Finally, cli-
nicians were not really aware of vitamin D deficiency at
that time. Since then, a relative vitamin D deficiency (<
20 ng/ml) has been reported in a large proportion of HIV-
patients, worsening after 12 months of ART [32]. In this
latter study, NNRTI were incriminated in the vitamin D
decline. On the other hand, several PI were shown to im-
pair synthesis of 25-OH D3 and 1,25-diOH-D3 in cells
[33,34]. A recent hypothesis suggests that ART, like other
xenobiotics, may also favour vitamin D degradation,
through the CYP24 hydroxylase [35,36]. Moreover, the de-
cline of 25-OH D3 might up-regulate PTH synthesis [37].
In agreement with this, hyperparathyroidism has been
reported upon ritonavir [38]. Apart from its role in bone
resorption, PTH stimulates renal 1α-hydroxylase and has
positive effects on osteoblast marker, like ALP and
osteocalcin [39,40]. Thus, we may hypothesize that a low
25-OH D3 would trigger secondary hyperparathyroidism,
which, in turn, would stimulate synthesis of 1,25-di-OH
D3 and of osteoblast differentiation factors. Up-regulation
of 1,25-di-OH D3 would be somewhat less pronounced
upon PI, due to possible impact of those drugs on 25-OH
D3 bioactivation [33]. Elevated calcemia would then result
from increased PTH and 1,25-di-OH D3. Increased PTH
might thus be a sensitive marker of bone remodelling and
of vitamin D defect in treated HIV-patients.
The low metabolite concentrations observed at baseline
may reflect a hypercatabolic situation in HIV-untreated
patients corroborating previous observations [41]. Follow-
ing ART introduction, glucose, lipids and albumin in-
creased, likely reflecting an improvement of the energetic
status associated with a better immuno-virological control.
Large randomised trials have demonstrated different ef-
fects of ART on metabolic markers. A recent study
showed the greatest increase in lipid parameters with a
treatment combining PI and NNRTI [42]. In our study,
most marked increases were for TG (+ 50%) with a spe-
cific effect of PI. PI-treated patients also experienced a
homogeneous gain in fat mass both in trunk and lower
limbs. Interestingly, other longitudinal studies have de-
scribed increases in lean and fat masses during the first
weeks upon ART, followed by a subsequent loss of limb
fat after 2 years, [43,44]. Thus likely, our follow-up
period was too short (< 2 years) to record any signifi-
cant fat redistribution, except for a homogeneous gain.
In our longitudinal study, we found that the decrease in
BMD was correlated with increased BMI, the latter be-
ing mostly attributable to a gain in fat mass. We specu-
late that PI might switch the differentiation program of
mesenchymal progenitor cells towards adipocytes, at
the expanse of osteoblast formation, as already hypoth-
esized [16].
Conclusion
In conclusion, despite the small size of the studied popula-
tion, our observations demonstrate an early effect of ART
on lipid and bone metabolisms. More specifically, PI lead
to a significant gain in fat mass correlated with a sharp
drop in BMD but active bone remodelling is evident with
all antiretroviral treatments, associated with low vitamin
D levels and hyperparathyroidism. In parallel, signs of
metabolic restoration are evident. However, early increases
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in lean and fat mass, triglycerides, waist circumference
and leptin are much more pronounced with PI.
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